Synthesis and Anticancer Properties of Silver(I) Complexes Containing 2,6-Bis(substituted)pyridine Derivatives

Abstract

Several new 2,6-bis(substituted)pyridine ligands and 2,6-bis(substituted)pyridine Ag(I) nitrate complexes were synthesized and characterized spectroscopically. The newly synthesized ligands include pyridine-2,6-bis(3-oxopropanenitrile) (1), pyridine-2,6-bis(2-cyano-N-phenyl-3-oxopropanethioamide) (2), and pyridine-2,6-bis((E)-2-(2-phenylhydrazono)-3-oxopropanenitrile) (3). The newly synthesized ligands and silver(I) complexes were evaluated for their in vitro anticancer activity against four human cancer cell lines including hepatocellular carcinoma (HePG2), lung adenocarcinoma (A549), colon carcinoma (HT29), and breast adenocarcinoma (MCF7). Most of the newly synthesized silver(I) complexes exhibited better activity than the ligands, and the results have been compared with doxorubicin as a reference drug.

Silver coordination compounds: A new horizon in medicine

“…4, 16 a-c), whose complexes have been tested against hepatocellular carcinoma (HePG2), lung adenocarcinoma (A549), colon carcinoma (HT29), and breast adenocarcinoma (MCF7), using doxorubicin as the reference drug. Most of the silver complexes in this series exhibited higher cytotoxic activity against tested cancer cell lines than doxorubicin, but their mechanism of action was not elucidated [84].…”

Metal complexes in cancer therapy – an update from drug design perspective

“… 65 The ligands and the complexes were evaluated in vitro with doxorubicin (reference compound) in hepatocellular carcinoma (HepG2), lung adenocarcinoma (A549), colon carcinoma (HT29) and breast adenocarcinoma (MCF7) using the MMT method. 65 All the synthesized complexes exhibited more significant activity more than the corresponding ligands, 65 and most of the prepared silver complexes exhibited outstanding cytotoxic activity against tested cancer cell line compared to the doxorubicin. 65 All these properties placed silver complexes as a promising metal complex to be targeted in future for chemotherapy.…”

Synthesis of moxifloxacin–Au (III) and Ag (I) metal complexes and their biological activities

“…A triplet at (δ 4. (Chiririwa and Muzenda 2014;Ali et al 2013;Efthimiadou et al 2006). This shift is due to the complexation and difference in the configuration of complexes than ligand.…”